Cargando…

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD

This real-world study compared the effectiveness of triple therapy (TT; long-acting muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled corticosteroids (ICSs)) versus dual bronchodilation (DB; LAMAs/LABAs) among patients with frequently exacerbating COPD. A matched historic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voorham, Jaco, Corradi, Massimo, Papi, Alberto, Vogelmeier, Claus F., Singh, Dave, Fabbri, Leonardo M., Kerkhof, Marjan, Kocks, Janwillem H., Carter, Victoria, Price, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715826/ https://www.ncbi.nlm.nih.gov/pubmed/31497610 http://dx.doi.org/10.1183/23120541.00106-2019

Ejemplares similares

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
por: Voorham, Jaco, et al.
Publicado: (2020)

Association between COPD exacerbations and lung function decline during maintenance therapy
por: Kerkhof, Marjan, et al.
Publicado: (2020)

The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
por: Kerkhof, Marjan, et al.
Publicado: (2020)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
por: Vogelmeier, Claus F., et al.
Publicado: (2022)

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands
por: van Boven, Job FM, et al.
Publicado: (2016)

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
por: Singh, Dave, et al.
Publicado: (2019)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

Dual Bronchodilator in the Era of Triple Therapy
por: Papaioannou, Andriana I, et al.
Publicado: (2020)

Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma
por: Price, David, et al.
Publicado: (2021)

Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review
por: Price, David, et al.
Publicado: (2016)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022)

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
por: Vogelmeier, Claus F., et al.
Publicado: (2020)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial
por: Bjermer, Leif, et al.
Publicado: (2021)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
por: Singh, Dave, et al.
Publicado: (2018)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Blood eosinophil count predicts treatment failure and hospital readmission for COPD
por: Kerkhof, Marjan, et al.
Publicado: (2020)

Development of a tool to detect small airways dysfunction in asthma clinical practice
por: Kocks, Janwillem, et al.
Publicado: (2023)

A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD
por: Ming, Simon Wan Yau, et al.
Publicado: (2020)

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017)

Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
por: Vogelmeier, Claus F, et al.
Publicado: (2021)

Matching the Inhaler to the Patient in COPD
por: Peché, Rudi, et al.
Publicado: (2021)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
por: Pascoe, Steven, et al.
Publicado: (2016)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
por: Singh, Dave, et al.
Publicado: (2019)

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
por: Price, David B, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9c95tiu52cjl2ihqtapoqnljrj